骨肉瘤患者癌症易感基因致病性胚系变异频率
欧洲裔患者中238个高关注癌症易感基因的致病/可能致病性变异负荷显著高于对照(P=1.3×10⁻¹⁸),28.0%患者携带此类变异,近四分之三位于常染色体显性基因或已知骨肉瘤相关癌症易感综合征基因。
要点
- 骨肉瘤患者中28.0%携带癌症易感基因致病/可能致病性胚系变异。
- 欧洲裔患者高关注基因变异负荷显著高于无癌对照(P=1.3×10⁻¹⁸)。
- 近四分之三变异位于常染色体显性基因或已知骨肉瘤相关综合征基因。
核心结论
- 约四分之一的未选择家族史的骨肉瘤患者携带高外显率胚系突变,需进一步随访分析及可能的遗传咨询和级联检测。
主要发现
- 欧洲裔患者中238个高关注癌症易感基因的致病/可能致病性变异负荷显著高于对照(732例 vs 994例,P=1.3×10⁻¹⁸)。
- 1004例骨肉瘤患者中281例(28.0%)携带癌症易感基因致病/可能致病性变异,近四分之三位于常染色体显性基因或已知骨肉瘤相关癌症易感综合征基因。
- 在既往未与骨肉瘤关联的基因(如CDKN2A、MEN1、VHL、POT1、APC、MSH2和ATRX)及Li-Fraumeni综合征相关基因TP53中观察到高于预期的致病/可能致病性变异频率。
临床怎么用
- 对骨肉瘤患者应考虑胚系基因检测,尤其针对常染色体显性癌症易感基因及已知骨肉瘤相关综合征基因。
- 检出高外显率胚系突变的患者应接受遗传咨询,并对其亲属进行级联检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Osteosarcoma, the most common malignant bone tumor in children and adolescents, occurs in a high number of cancer predisposition syndromes that are defined by highly penetrant germline mutations. The germline genetic susceptibility to osteosarcoma outside of familial cancer syndromes remains unclear. OBJECTIVE: To investigate the germline genetic architecture of 1244 patients with osteosarcoma. DESIGN, SETTING, AND PARTICIPANTS: Whole-exome sequencing (n = 1104) or targeted sequencing (n = 140) of the DNA of 1244 patients with osteosarcoma from 10 participating international centers or studies was conducted from April 21, 2014, to September 1, 2017. The results were compared with the DNA of 1062 individuals without cancer assembled internally from 4 participating studies who underwent comparable whole-exome sequencing and 27 173 individuals of non-Finnish European ancestry who were identified through the Exome Aggregation Consortium (ExAC) database. In the analysis, 238 high-interest cancer-susceptibility genes were assessed followed by testing of the mutational burden across 736 additional candidate genes. Principal component analyses were used to identify 732 European patients with osteosarcoma and 994 European individuals without cancer, with outliers removed for patient-control group comparisons. Patients were subsequently compared with individuals in the ExAC group. All data were analyzed from June 1, 2017, to July 1, 2019. MAIN OUTCOMES AND MEASURES: The frequency of rare pathogenic or likely pathogenic genetic variants. RESULTS: Among 1244 patients with osteosarcoma (mean [SD] age at diagnosis, 16 [8.9] years [range, 2-80 years]; 684 patients [55.0%] were male), an analysis restricted to individuals with European ancestry indicated a significantly higher pathogenic or likely pathogenic variant burden in 238 high-interest cancer-susceptibility genes among patients with osteosarcoma compared with the control group (732 vs 994, respectively; P = 1.3 × 10-18). A pathogenic or likely pathogenic cancer-susceptibility gene variant was identified in 281 of 1004 patients with osteosarcoma (28.0%), of which nearly three-quarters had a variant that mapped to an autosomal-dominant gene or a known osteosarcoma-associated cancer predisposition syndrome gene. The frequency of a pathogenic or likely pathogenic cancer-susceptibility gene variant was 128 of 1062 individuals (12.1%) in the control group and 2527 of 27 173 individuals (9.3%) in the ExAC group. A higher than expected frequency of pathogenic or likely pathogenic variants was observed in genes not previously linked to osteosarcoma (eg, CDKN2A, MEN1, VHL, POT1, APC, MSH2, and ATRX) and in the Li-Fraumeni syndrome-associated gene, TP53. CONCLUSIONS AND RELEVANCE: In this study, approximately one-fourth of patients with osteosarcoma unselected for family history had a highly penetrant germline mutation requiring additional follow-up analysis and possible genetic counseling with cascade testing.
引用
- Mirabello L, Zhu B, Koster R, et al. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncol. 2020. PMID: 32191290. doi:10.1001/jamaoncol.2020.0197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。